Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial.
Jiwon KimChang-Min ChoiWonjun JiJae Cheol LeePublished in: Thoracic cancer (2023)
Nivolumab maintenance following platinum-based chemotherapy did not show clinical benefits after EGFR-TKI failure in patients with EGFR-mutant NSCLC.
Keyphrases
- small cell lung cancer
- tyrosine kinase
- epidermal growth factor receptor
- advanced non small cell lung cancer
- open label
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- locally advanced
- clinical trial
- stem cells
- wild type
- patient reported outcomes
- phase ii study
- mesenchymal stem cells